Abeona Therapeutics Inc vs EHang Holdings Ltd - ADR — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while EHang Holdings Ltd - ADR trades at $5.79 (market cap $437.63M). The key difference: Abeona Therapeutics Inc and EHang Holdings Ltd - ADR are close in size by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| ABEO | EH | |
|---|---|---|
Market Cap | $421.19M | $437.63M |
Sector | Health | Industrials |
52-Week High | $7.45 | $19.44 |
52-Week Low | $4.17 | $4.90 |
Enterprise Value | $276.10M | $376.84M |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
EHang Holdings (EH) trades at $5.70, up 0.18% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported Q1 2026 revenue of $418 million, with a net loss of $276 million, reflecting ongoing profitability challenges despite a high gross margin of 61.53%. Recent news includes the successful pilotless eVTOL flight in Kazakhstan, highlighting operational progress amid a volatile year for air taxi stocks.
The outlook remains speculative, with significant growth potential in the advanced air mobility market offset by persistent losses and competitive pressures. Risks include execution hurdles and funding needs, while analyst sentiment is divided with a consensus price target of $6.97 suggesting modest upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →